About Us

Mazal Plant Pharmaceuticals, Inc. is an early-stage whole plant pharmaceutical development company whose mission is to develop treatments for chronic diseases from combinations of whole plants and to build shareholder value through negotiated relationships with strategic partners to fund commercialization and marketing of these treatments on a stand-alone or combination basis.

Mazal�s lead candidate, MAHDL01, is a unique combination of whole plants that has shown a potential in early clinical studies to increase the HDL/LDL ratio. Controlled clinical studies have shown evidence that increasing this ratio in adults may improve overall cardiovascular health.

Mazal believes that MAHDL01 may also demonstrate an improved side effect profile due to its comprising natural components in contrast to commonly synthesized compounds.

Mazal is currently planning a Phase I/II, double-blind, placebo and active-controlled, randomized, parallel-group study to evaluate the safety and efficacy of MAHDL01 alone and as an adjunct to statin therapy, versus placebo or statin therapy alone, in increasing HDL in subjects with low HDL cholesterol (hypoalphalipoproteinemia) who are maintaining a restricted diet.

Chaim J. Lieberman, CEO
Mr. Lieberman is an entrepreneur of plant pharmaceutical biotechnology, with over twenty years experience. He currently holds executive positions in several companies. He achieved the first FDA IND on a Whole Plant Pharmaceutical Drug.

Meir S. Silver, Ph.D., President and Scientific Director
Dr. Silver has over fifteen years experience in Research and Development, Clinical Research and Development in both medical devices and biotechnology. He has held positions of increasing responsibility at Siemens Medical Systems and at Philips Medical Systems, and several successful start-up companies. He holds a B.S. in physics with honors from Lafayette College, an M. A. in Biophysics and a Ph.D. in Electrical Engineering and Computer Science from The Johns Hopkins University.

Jeremy Werblowsky, MBA, CFO and Director
Mr. Jeremy Werblowsky MBA, received his BA in Economics and MBA in Finance from Bar-Ilan University in Israel. He has 10+ years experience working in the financial and business fields. Before joining Mazal he has previously worked as a Global Director of Finance for a multi-national company and most recently was VP of Sales and Marketing for a growing Internet Company. He also has two years experience working as a consultant for Ernst & Young.